en · de · es · pt
cjc-1295-notes.peptides6155.com › Blog › Cjc-1295 Background And Mechanism — Deep Dive

Cjc-1295 Background And Mechanism — Deep Dive

By Editorial Desk · published 2026-01-31 · last reviewed 2026-03-20 · Blog

somatotroph is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-03-20. Numbers and descriptions here follow the published literature rather than marketing material.

CJC-1295 Background and Mechanism

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight (with DAC)~3647 DaCalculated from the full amino acid sequence
Molecular weight (without DAC)~3368 DaMod GRF(1-29) variant
AppearanceWhite lyophilized powderTypical form supplied for research
SolubilitySoluble in waterDissolves in aqueous buffers
Receptor targetGHRH receptorExpressed on pituitary somatotroph cells

Analytical Characterization and Storage

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Related pages on this site

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Handling Storage and Quality Control

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Further detail

== Further reading. == Mendelsohn, John Andrew. "Cultures of bacteriology: Formation and transformation of a science in France and Germany, 1870-1914" (PhD dissertation, Princeton University' ProQuest Dissertations & Theses, 1996. 9701218).

== Production and content == Finely textured meat is produced by heating boneless beef trimmings (the last traces of skeletal muscle meat, scraped, shaved, or pressed from the bone) to 107–109 °F (42–43 °C), removing the melted fat by centrifugal force using a centrifuge, and flash freezing the remaining product to 15 °F (−9 °C) in 90 seconds in a roller press freezer. The roller press freezer is a type of freezer that was invented in 1971 by BPI CEO Eldon Roth that can "freeze packages of meat in two minutes" and began to be used at Beef Products Inc. in 1981. The lean finely textured beef is added to ground beef as a filler or to reduce the overall fat content of ground beef. In March 2012 about 70% of ground beef sold in US supermarkets contained the product. It is also used as a filler in hot dogs produced in the United States. The recovered beef material is extruded through long tubes that are thinner than a pencil, during which time at the BPI processing plant, the meat is exposed to gaseous ammonia. At Cargill Meat Solutions, citric acid is used to kill bacteria such as E. coli and Salmonella instead. Gaseous ammonia in contact with the water in the meat produces ammonium hydroxide. The ammonia sharply increases the pH and damages microscopic organisms, the freezing causes ice crystals to form and puncture the organisms' weakened cell walls, and the mechanical stress destroys the organisms altogether. The product is finely ground, compressed into pellets or blocks, flash frozen and then shipped for use as an additive.

=== Rehabilitation and exercise === Cardiac rehabilitation benefits many who have experienced myocardial infarction, even if there has been substantial heart damage and resultant left ventricular failure. It should start soon after discharge from the hospital. The program may include lifestyle advice, exercise, social support, as well as recommendations about driving, flying, sports participation, stress management, and sexual intercourse. Returning to sexual activity after myocardial infarction is a major concern for most patients, and is an important area to be discussed in the provision of holistic care. In the short-term, exercise-based cardiovascular rehabilitation programs may reduce the risk of a myocardial infarction, reduces a large number of hospitalizations from all causes, reduces hospital costs, improves health-related quality of life, and has a small effect on all-cause mortality. Longer-term studies indicate that exercise-based cardiovascular rehabilitation programs may reduce cardiovascular mortality and myocardial infarction.

Sources: en.wikipedia.org

Supporting material

The medical examiner's office collected "about 10,000 unidentified bone and tissue fragments that cannot be matched to the list of the dead." Bone fragments were still being found in 2006 by workers who were preparing to demolish the damaged Deutsche Bank Building. In 2010, a team of anthropologists and archaeologists searched for human remains and personal items at the Fresh Kills Landfill, where 72 more human remains were recovered, bringing the total found to 1,845. As of 2011, DNA profiling was ongoing in an attempt to identify additional victims. In 2014, three coffin-size cases carrying 7,930 unidentified remains were transferred to a medical examiner's repository located at the same site as the National September 11 Memorial & Museum. Victims' families are permitted to visit a private "reflection room" which is closed to the public. The choice to place the remains in an underground area attached to a museum has been controversial; families of some victims have attempted to have the remains instead interred in a separate, above-ground monument. In August 2017, the 1,641st victim was identified as a result of newly available DNA technology, and a 1,642nd during July 2018. Three more victims were identified in October 2019, two in September 2021 and an additional two in September 2023. As of 2025, 1,103 victims remain unidentified, amounting to 40% of the deaths in the World Trade Center attacks. On September 25, 2023, the FDNY reported that the department had now lost the same number of members to 9/11-related illnesses as it did on the day of the attacks.

== A == AAS – Atomic absorption spectroscopy AED – Auger electron diffraction AES – Auger electron spectroscopy AFM – Atomic force microscopy AFS – Atomic fluorescence spectroscopy Analytical ultracentrifugation APFIM – Atom probe field ion microscopy APS – Appearance potential spectroscopy ARPES – Angle resolved photoemission spectroscopy ARUPS – Angle resolved ultraviolet photoemission spectroscopy ATR – Attenuated total reflectance

== Toxicity == An in silico Study analyzing potential risks of 3-HO-PCE, along with other related substances, found multiple potential risks. One such risk was a high probability of hERG blockades, suggesting that QT-prolongation could be present in use. The lungs, liver, and blood were all found to be prominent likely toxicity targets of this class of drugs. The LD50 of 3-HO-PCE and related substances in rats was consistently between 200-630mg/kg orally, indicating moderate oral toxicity.

Action Game – Grand Theft Auto: Vice City Adventure Game – The Legend of Zelda: The Wind Waker Animation or Intro – Soulcalibur II (Jame Chung Edition) Children's Game – EyeToy: Play Design – Grand Theft Auto: Vice City Game Boy Advance Game – Advance Wars 2: Black Hole Rising Game on Any Platform – The Year's Best Game – Call of Duty GameCube – Metroid Prime Mobile Game – Tony Hawk's Pro Skater Multiplayer – Battlefield 1942 Original Music – Harry Potter and the Chamber of Secrets PC – Grand Theft Auto: Vice City PS2 – Grand Theft Auto: Vice City Racing – Project Gotham Racing 2 Sound – Grand Theft Auto: Vice City Sports – FIFA Football 2004 Strategy – Advance Wars 2: Black Hole Rising Sunday Times Reader Award for Games – Grand Theft Auto: Vice City Technical Achievement – EyeToy: Play Xbox – Star Wars: Knights of the Old Republic Special Award (Games) – Chris Deering

Sources: en.wikipedia.org

Frequently asked questions

What distinguishes CJC-1295 from natural GHRH?

The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.

Why does the DAC group matter?

The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.

Is CJC-1295 an approved medicine?

It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

Network